• Publications
  • Influence
Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.
PURPOSE Novel therapies to treat chronic obstructive pulmonary disease are highly desirable. The safety, tolerability, and pharmacokinetic (PK) parameters of nemiralisib, a phosphoinositide 3-kinaseExpand
  • 10
  • 2
Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
BACKGROUND While current therapies reduce symptoms in chronic obstructive pulmonary disease (COPD) patients, substantial unmet need remains and novel treatments are highly desired. PhosphoinositideExpand
  • 33
Leveraging the Advantages Offered by Microfluidics to Enhance the Drug Discovery Process
Why is GlaxoSmithKline (GSK) interested in Microsystems Technology (MST) and how can MST be utilised in organic synthesis and biological screening for lead optimisation? The highly competitive worldExpand
  • 22
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults
Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase involved in leukocyte recruitment and activation. Activation of PI3Kδ has been linked to airway inflammation and asthma pathogenesis. ThisExpand
  • 11
Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib
Nemiralisib (GSK2269557), a potent inhaled inhibitor of phosphoinositide 3-kinase δ (PI3Kδ), is being developed for the treatment of respiratory disorders including chronic obstructive pulmonaryExpand
  • 5
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered
Introduction: GSK2269557 was investigated as a dry powder formulation in a double blind, placebo controlled study in healthy cigarette smokers. Safety, tolerability, PK and PD data were collectedExpand
  • 3
Systemic Exposures of Fluticasone Propionate and Salmeterol Following Inhalation via Metered Dose Inhaler with the Mini Spacer Compared with the Aerochamber Plus Spacer.
BACKGROUND The Mini Spacer has been developed for use with Ventolin(®) metered dose inhalers (MDIs) to improve accessibility to affordable spacers in developing countries. To ensure patient safety isExpand
  • 2
The Development of Integrated Microfluidic Chemistry Platforms for Lead Optimisation in the Pharmaceutical Industry
During the last decade, GlaxoSmithKline Pharmaceuticals (GSK) has carried out much of the seminal work in the area of micro fluidics and micro flow assay for lead optimisation. It has pioneered andExpand
  • 1
Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kδ) GSK2269557, Delivered via the ELLIPTATM Device to Healthy
Introduction: GSK2269557 was investigated in a single centre, three part, double blind (charcoal open-label), placebo controlled trial in healthy subjects following inhaled delivery. Safety,Expand